共 26 条
- [2] 755 5-YEAR ENTECAVIR TREATMENT IN NUC-NA?VE, FIELD-PRACTICE PATIENTS WITH CHRONIC HEPATITIS B SHOWED EXCELLENT VIRAL SUPPRESSION AND SAFETY PROFILE BUT NO PREVENTION OF HCC IN CIRRHOTICS[J] . P. Lampertico,R. Soffredini,M. Viganò,E. Minola,G. Cologni,M. Rizzi,S. Zaltron,A. Vavassori,F. Castelli,E. Angeli,G.A. Gubertini,C. Magni,G. Rizzardini,A. Testa,G. D’Offizi,M. Vinci,G. Pinzello,E. Fatta,S. Fargion,S. Colombo,O. Fracassetti,P. Del Poggio,B. Coco,M.R. Brunetto,M. Andreoletti,A. Colli,M. Fasan
- [3] 772 SERUM HEPATITIS B SURFACE ANTIGEN LEVELS DURING FIVE YEARS ENTECAVIR THERAPY IN ASIAN CHRONIC HEPATITIS B PATIENTS[J] . W.-K. Seto,Y.-F. Lam,J. Fung,D.K.-H. Wong,C.-L. Lai,M.-F. Yuen.Journal of Hepatology . 2013
- [4] EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection[J] . European Association for the Study of the Liver.Journal of Hepatology . 2012 (1)
- [5] Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study[J] . Patrick Marcellin,Edward Gane,Maria Buti,Nezam Afdhal,William Sievert,Ira M Jacobson,Mary Kay Washington,George Germanidis,John F Flaherty,Raul Aguilar Schall,Jeffrey D Bornstein,Kathryn M Kitrinos,G Mani Subramanian,John G McHutchison,E Jenny Heathcote.The Lancet . 2012
- [6] Management of treatment failure in chronic hepatitis B[J] . Fabien Zoulim,Stephen Locarnini.Journal of Hepatology . 2012